Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on March 31, 2025
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
GlobeNewswire
·
March 31, 2025
BEDFORD, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to redefining the retina experience, today announced that the Company will participate in two investor conferences …
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 31, 2025
– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 …
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates
GlobeNewswire
·
March 31, 2025
Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, …
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
GlobeNewswire
·
March 31, 2025
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced that the National Medical Products Administration (NMPA) of the People …
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
GlobeNewswire
·
March 31, 2025
-- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization …
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
GlobeNewswire
·
March 31, 2025
Over $20M raised in Q1 with nearly $15M cash on hand No debt, no preferred equity, and no warrants with strike prices near the current market Nasdaq compliant: fully meets bid price and shareholder equity requirements Pivotal CLARITY trial fully funded …
Keros Therapeutics Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers
GlobeNewswire
·
March 31, 2025
Trial achieved key objectives for safety, tolerability, pharmacokinetics and pharmacodynamics Clinical data from this trial, together with preclinical data, support the therapeutic potential of KER-065 for broad impact in Duchenne muscular dystrophy (“DMD …
Glucofreedom Drops Reviews (EXPOSED) Gluco Revive BloodSugar Control ORDER NOW!
GlobeNewswire
·
March 31, 2025
AURORA, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- The maximum number of people are seen to have blood sugar these days. While for many the reason is not caring for their health as it should be, the other reason includes things like wrong food choices. This …
SBC Medical Accelerates Multi-Brand Strategy with ‘SBC NEO Skin Clinic’ Expansion
GlobeNewswire
·
March 31, 2025
TOKYO, March 31, 2025 (GLOBE NEWSWIRE) -- Shonan Beauty Clinic, supported by SBC Medical Group Holdings Incorporated (Nasdaq: SBC) ("SBC Medical," or the "Company") in management services, today announced the expansion of its multi-brand strategy as part …